A Randomised Double-blind, Placebo-controlled, Phase 1b Trial to Evaluate the Safety, Tolerability and Protective Efficacy of the Influenza Vaccine Candidate, FLU-v, in an Influenza Challenge Model
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Influenza
- Sponsor
- PepTcell Limited
- Enrollment
- 32
- Locations
- 1
- Primary Endpoint
- Adverse Events (AEs)
- Status
- Completed
- Last Updated
- 13 years ago
Overview
Brief Summary
The purpose of this research is to study the safety, tolerability and effectiveness of the investigational influenza vaccine in healthy volunteers infected with an attenuated influenza A virus.
Detailed Description
The investigational influenza vaccine (FLU-v) contains multiple highly conserved T cell epitopes that are present on most influenza viruses, which have been identified as reactive in different human leukocyte antigen (HLA) populations; thus making it unlikely that anybody in the vaccinated population would be unable to mount an immune response to at least one of the epitopes contained in the vaccine. In this study up to 44 will be vaccinated with the FLU-v experimental vaccine or a placebo in a 1:1 ratio. Volunteers will attend a screening visit, a vaccination visit, a 10-11 day overnight stay in a quarantine facility, and a follow-up visit to the P1 clinic. Three weeks after being vaccinated with FLU-v or placebo, 30 volunteers will be taken to a Quarantine Unit to be exposed to the attenuated H3N2 study virus and then monitored by study physicians and nurses for a 10-11 day period. The other 14 volunteers will be held in reserve as back-ups. If fewer than 30 of the volunteers who travel to the Quarantine Unit are eligible to be exposed to the study virus, then volunteers who have been kept in reserve will be used. Following discharge from the Quarantine Unit, volunteers will attend one study follow-up visit, 28 days after exposure to the study virus. Assessments will take place and samples will be taken from volunteers.
Investigators
Eligibility Criteria
Inclusion Criteria
- •General good health determined by a screening evaluation ≤120 days prior to IMP administration and on the day of admittance to quarantine
- •Using methods of contraception, (e.g. spermicidal gel plus condom) for the entire duration of the study, up to the Study Completion visit, and refrain from fathering a child in the three months following study drug administration.
- •Negative HIV, hepatitis B and C antibody screens
- •Negative class A drugs, alcohol and nicotine screen
- •Seronegative (≤10 HAI) for challenge virus
- •Have not been vaccinated for influenza virus since 2006 (as determined in the medical history) or had a known influenza-like illness in the current season, defined as in the last 12 months
Exclusion Criteria
- •Presence of any significant acute or chronic, uncontrolled medical or psychiatric illness, including but not exclusive to the conditions listed in Appendix 2, that in the view of the Investigator is associated with increased risk of complications of respiratory viral illness
- •Abnormal pulmonary function as evidenced by clinically significant abnormalities in spirometry
- •Presence of household member or close contact who is: less than 3 years of age; known immunodeficient; receiving immunosuppressants; undergoing/soon to undergo chemotherapy; diagnosed with emphysema or COPD; is elderly residing in a nursing home; severe lung disease or medical condition; received a transplant (bone marrow or solid organ)
- •History of asthma, COPD, pulmonary hypertension, reactive airway disease, or any chronic lung condition of any aetiology
- •Any laboratory test or ECG which is abnormal and deemed by the investigator to be clinically significant
- •Venous access inadequate for phlebotomy demands
- •Regular daily smokers during the 6 months prior to study entry or those who have a significant history of any tobacco use at any time
- •Subject is diabetic
- •History or evidence of autoimmune disease or known impaired immune responsiveness
- •Recent and/or recurrent history of autonomic dysfunction
Outcomes
Primary Outcomes
Adverse Events (AEs)
Time Frame: Day -21 to Day 28
The primary safety endpoint for the vaccination phase of the study is the evaluation of all AEs occurring up to Day 28 (final follow-up). AE details will be collected by subject questioning and review of a subject self-assessment diary card (completed for Days -21 to -14) at the clinic visit on Day -2
Secondary Outcomes
- Safety of FLU-v(Days -21 to 28)
- Post-innoculation symptoms(Days 0 to 28)
- Post-innoculation virology(6 days following inoculation)
- Post-innoculation fever(Days -21 to 28)
- Protective Efficacy (PE)(Day 1 to 5 post-viral challenge)